Recognizing the World’s Most Exceptional Destinations: Nominations Now Open for the Inaugural TOURISE Awards
2.6.2025 21:10:00 CEST | Business Wire | Press Release
The TOURISE Awards officially launched today as a new global benchmark celebrating excellence in tourism destinations. Created to honor places that are shaping the future of travel, the Awards spotlight destinations delivering meaningful, memorable, and measurable value across the traveler journey. Nominations are now open to individual travelers, industry professionals, and organizations passionate about recognizing the world’s most exceptional places.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250602550866/en/
Recognizing the World’s Most Exceptional Destinations: Nominations Now Open for the Inaugural TOURISE Awards (Infographic: AETOSWire)
The TOURISE Awards are an extension of the TOURISE platform powered by Saudi Arabia’s Ministry of Tourism and announced via a virtual press conference on May 22, 2025.
In line with the TOURISE ethos, the Awards take a bold stance recognizing destinations with a strong sense of identity, measurable impact, and responsible management. Eligible destinations must have (i) a defined geographic scope (a city, region or site), (ii) a distinct identity and character that stems from culture, landscapes and attractions that shape how the destination is perceived by travelers, and finally (iii) must be backed by a tourism governing body responsible for ensuring a destination is effectively managed.
The TOURISE Awards feature five distinct award categories: Best Arts and Culture Destination, Best Adventure Destination, Best Food and Culinary Destination, Best Shopping Destination, and Best Entertainment Destination. In addition, a flagship Best Overall Destination award will recognize the destination that excels across all aspects of the traveler experience — setting a new global benchmark as the most exceptional place to visit.
Jean-Philippe Cossé, CEO of TOURISE, said: “Tourism is not just a key economic engine — it’s a powerful connector of cultures, a builder of communities, and a driver of sustainable change. As the industry undergoes a bold transformation, it’s more crucial than ever to spotlight the destinations that are leading with vision, purpose, and resilience. The TOURISE Awards are our tribute to those extraordinary places that don’t just welcome travelers — they inspire them, challenge the status quo, and push the boundaries of what tourism can achieve. These awards put destinations at the center of the global conversation, celebrating the pioneers who are shaping the future of travel.”
The TOURISE Awards will be judged by an independent jury panel comprised of a powerhouse of cross-industry trailblazers from the worlds of travel and tourism, fashion, culinary, art, retail, culture, adventure and entertainment:
- Filip Boyen, Former CEO, Forbes Travel Guide;
- Michael Ellis, Former Global Director, Michelin Guides;
- Fiona Jeffery, Former Chair, World Travel Market; Former Chair Tourism for Tomorrow Awards;
- Renaud de Lesquen; Former CEO, Givenchy, Former President Dior AM;
- Lars Nittve, Former Founding Director, Tate Modern;
- Albert Read, Former Managing Director , Conde Nast;
- Caroline Rush, Former CEO, British Fashion Council;
- Omar Samra, UN Goodwill Ambassador, Mountaineer and Polar Explorer
- Bernold Schroeder, Former CEO, Kempinski; Pan Pacific.
Eligible destinations will be evaluated across 10 assessment criteria, grouped into three key areas, which make up the destination experience: offering, value, convenience. Judges will assess how destinations perform across these areas — considering what they offer, how accessible and visitor-friendly they are, the overall value they provide, and most importantly, the quality and impact of the experience. This includes looking at factors such as authenticity, innovation, inclusion, sustainability, accessibility, accommodation variety, and safety, all of which contribute to a destination’s ability to deliver a meaningful and memorable journey.
The winners of the inaugural TOURISE Awards will be announced at the TOURISE Summit, taking place in Riyadh from November 11 to 13. The Summit will bring together leading voices from across tourism, travel, investment, and innovation — from heads of state and visionary CEOs to creators, disruptors, and global investors. It will serve as a platform to spark bold ideas, build transformative partnerships, and shape new standards for the future of travel.
Have your say in who receives the first TOURISE Awards for the world’s most exceptional tourism destinations by nominating the destination you think makes a difference on the awards portal https://www.tourise.com/en/awards. Nominations are open from June 2nd to July 9th.
To find out more about TOURISE www.tourise.com.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602550866/en/
Contacts
For media inquiries, please contact:
Fahad Al Bahiti
media@tourise.com
Media kit: https://www.dropbox.com/t/EPahFKdbtzozFHUz -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.dropbox.co
m%2Ft%2FEPahFKdbtzozFHUz&esheet=54263798&newsitemid=20250602550866&lan=en-US&anc
hor=https%3A%2F%2Fwww.dropbox.com%2Ft%2FEPahFKdbtzozFHUz&index=4&md5=c60f365d917
20dfa1ff49e78128b32a9
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom